- Received FDA approval for ZEVASKYN⢠(prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) -
Related Questions
How will the FDA approval of ZEVASKYN⢠affect Abeona's revenue projections and cash flow in the coming quarters?
What is the expected market size and adoption rate for ZEVASKYN⢠in the RDEB patient population?
Will the approval trigger any milestone payments, reimbursements, or pricing negotiations with insurers?
How does the pricing strategy for ZEVASKYN⢠compare to other geneâtherapy or cellâbased treatments?
What are the production capacity and scalability plans for the autologous cellâbased therapy, and could supply constraints impact earnings?
Does the Q2 2025 financial performance show improvement in operating margins or R&D efficiency relative to prior periods?
How does Abeona's pipeline and this newly approved product position the company against competitors in the rareâdisease geneâtherapy space?
Are there any outstanding regulatory or litigation risks that could affect the commercial rollout of ZEVASKYN�
What guidance is management providing for Q3 and fullâyear 2025 earnings after the FDA approval?
How might this FDA approval influence analyst sentiment and target price revisions for ABEO?